Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Jacobson, T. A.    Related Articles in PubMed    PubMed Citation    PubMed

PERSPECTIVE

"The Lower the Better" in Hypercholesterolemia Therapy: A Reliable Clinical Guideline?

Terry A. Jacobson, MD

3 October 2000 | Volume 133 Issue 7 | Pages 549-554

Since the publication of the second set of guidelines by the National Cholesterol Education Program, a solid body of data from landmark clinical studies has demonstrated that reduction in low-density lipoprotein (LDL) cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ("statin") therapy sharply diminishes the risk for coronary artery disease. These trials include the Scandinavian Simvastatin Survival Study, the West of Scotland Coronary Prevention Study, the Air Force/Texas Coronary Atherosclerosis Prevention Study, the Cholesterol and Recurrent Events investigation, and the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. Coronary event rates and, in some cases, all-cause mortality decreased significantly after about 5 years of statin therapy in patients at risk for and those who had coronary artery disease at baseline. In contrast, recent subgroup analyses of these pivotal studies have in the aggregate challenged the premise that lower LDL cholesterol levels necessarily lead to further declines in risk for coronary artery disease, particularly among the patients most likely to be seen by the clinician: those with moderately elevated or normal cholesterol profiles. Indeed, when LDL cholesterol levels are in this range, further lowering with statin therapy elicits diminishing returns in terms of coronary event rates. These findings are readily accommodated by the curvilinear, or log-linear, model between serum cholesterol level and risk for coronary artery disease, which is predicated on data from large epidemiologic studies. In light of the current climate involving competing health care costs, the pursuit of progressively diminishing returns in terms of reductions in coronary artery disease risk through more aggressive lowering of LDL cholesterol levels appears to be unwarranted. Until data are published from ongoing randomized, clinical trials that can more effectively resolve the clinical utility of aggressive lipid-lowering strategies to improve coronary event rates, a prudent, evidence-based strategy seems warranted.

Author and Article Information

From the Department of Medicine, Emory University, Atlanta, Georgia.

Requests for Single Reprints: Terry A. Jacobson, MD, Office of Health Information and Disease Prevention, Emory University, Thomas Glenn Building, 69 Butler Street, SE, Atlanta, GA 30303; e-mail, tjaco02{at}emory.edu.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

				G. Onder, S. Volpato, R. Liperoti, C. D'Arco, C. Maraldi, R. Fellin, R. Bernabei, F. Landi, and on Behalf of the GIFA Investigators Total serum cholesterol and recovery from disability among hospitalized older adults. J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2006; 61(7): 736 - 742. [Abstract] [Full Text] [PDF]

				J. T. van Wyk, M. A. M. van Wijk, P. W. Moorman, and J. van der Lei Cross-sectional Analysis of Guidelines on Cardiovascular Disease Risk Factors: Going to Meet the Inconsistencies Med Decis Making, January 1, 2006; 26(1): 57 - 62. [Abstract] [PDF]

				J. T. van Wyk, M. A.M. van Wijk, M. C.J.M. Sturkenboom, P. W. Moorman, and J. van der Lei Identification of the Four Conventional Cardiovascular Disease Risk Factors by Dutch General Practitioners Chest, October 1, 2005; 128(4): 2521 - 2527. [Abstract] [Full Text] [PDF]

				M. Safford, L. Eaton, G. Hawley, M. Brimacombe, M. Rajan, H. Li, and L. Pogach Disparities in Use of Lipid-Lowering Medications Among People With Type 2 Diabetes Mellitus Arch Intern Med, April 28, 2003; 163(8): 922 - 928. [Abstract] [Full Text] [PDF]

				F. M. Sacks Low-density lipoprotein lowering therapy: an analysis of the options J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2135 - 2138. [Full Text] [PDF]

				P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina Statins and stroke: evidence for cholesterol-independent effects Eur. Heart J., December 2, 2002; 23(24): 1908 - 1921. [PDF]

				C. Galman, B. Angelin, and M. Rudling Prolonged Stimulation of the Adrenals by Corticotropin Suppresses Hepatic Low-Density Lipoprotein and High-Density Lipoprotein Receptors and Increases Plasma Cholesterol Endocrinology, May 1, 2002; 143(5): 1809 - 1816. [Abstract] [Full Text] [PDF]

				R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]